tyrphostin ag-17 + l-carnitine tartrate

**Tyrphostin AG-17 + l-carnitine tartrate** is a fixed-dose combination of two small molecules: tyrphostin AG-17, a selective inhibitor of the platelet-derived growth factor receptor (PDGFR) tyrosine kinase with additional mitochondrial uncoupling effects, and l-carnitine tartrate, a dietary supplement that facilitates fatty acid transport into mitochondria. Tyrphostin AG-17 acts as an anti-proliferative and pro-apoptotic agent, primarily via PDGFR tyrosine kinase inhibition, cyclin-dependent kinase 2 (cdk2) inhibition, and induction of mitochondrial dysfunction and cellular apoptosis. The combination has been studied in early clinical trials for safety and pharmacokinetics in healthy volunteers, and tyrphostin AG-17 has been explored preclinically for potential benefit in oncology and obesity models. The formulation is intended for oral administration.

Other names

3,5-di-tert-butyl-4-hydroxybenzylidenemalononitrile + l-carnitine tartratealpha-cyano-(3,5-di-t-butyl-4-hydroxy)cinnamonitrile + l-carnitine tartrate[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylenepropanedinitrile + l-carnitine tartrate